|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
FEBRUARY 7, 2005
Biosite's Robust Health  Biosite (BSTE
) is a little-known diagnostics outfit whose shares are dynamite -- blasting from 27 last February to 59.07 on Jan. 26. "It was our top performer in 2004," says Rodney Hathaway of Heartland Advisors, which has yet to sell any of its shares, bought at 30. Biosite's tests are used in 50% of U.S. hospitals -- and overseas -- mainly to detect heart attacks. Biosite "serves a niche market with strong growth prospects," says Hathaway. Driving the growth is Biosite's 70% share of the total market for so-called BNP blood tests for heart failure. Results are available within minutes. Despite the stock's huge gains, he adds, it has room to run -- to more than 70 in a year. He sees the company earning $2.34 a share in 2004, $2.50 in 2005, and $3.20 in 2006, up from 2003's $1.50. A fresh catalyst for Biosite: a new test, Triage Stroke Panel, to be used along with CT scans for quick diagnosis of cerebral ischemia, or strokes. Biosite has asked for Food & Drug Administration approval to market it. The FDA could rule on the application by yearend. Hathaway says there is an unmet need for a fast and effective test for strokes. Theodore Huber of Wachovia Securities (WB
), noting Biosite's "healthy product pipeline and strong prospects to beat earnings estimates in 2005," rates the stock "outperform."
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version
